Matthew Smith MD PhD

Oncology•Boston, MA

Genitourinary Oncology, Hematologic Oncology

Director, MGH Genitourinary Malignancies Program

Join to View Full Profile

55 Fruit StBoston, MA 02114
Phone+1 617-724-5257
Fax+1 617-726-4899

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
Duke University School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1994 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 2
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy Start of enrollment: 2006 Mar 01
Completed
Phase 3
Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2002 Nov 01
Completed
Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer Start of enrollment: 2006 Aug 01
Completed
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors Start of enrollment: 2007 Sep 01
Completed
Phase 2
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 1
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 Jan 20
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
Arun A Azad, Louise Kostos, Neeraj Agarwal, Gerhardt Attard, Ian D Davis
European Urology. 2025-04-01
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients ...
Kim N Chi, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou, Gerhardt Attard
Future Oncology. 2025-03-30
Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a...
Fred Saad, Maha H A Hussain, Bertrand Tombal, Karim Fizazi, Ken Mastris
Future Oncology. 2025-03-25

Other

Initial hormone therapy for metastatic prostate cancer
Smith MR, Lee RJ
http://www.uptodate.com/contents/initial-hormone-therapy-for-metastatic-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09
Side effects of androgen deprivation therapy
Smith MR, Crawford ED
http://www.uptodate.com/contents/side-effects-of-androgen-deprivation-therapy
UpToDate, Wolters Kluwer Health - 2013-03-27

Press Mentions

Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate CancerFebruary 17th, 2022
Another PARP Inhibitor Active in BRCA-Mutant Prostate CancerFebruary 8th, 2022
Accelerating Precision Medicine in Metastatic Prostate CancerNovember 17th, 2020
Join now to see all